Epitranscriptomic Therapies Market Growth Is Reshaping Competitive Advantage Across The Industry
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Epitranscriptomic Therapies Market Forecast: What Market Value Is Expected By 2030?
The epitranscriptomic therapies market has experienced substantial growth in recent years. It is forecast to increase from $1.56 billion in 2025 to $1.9 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 21.6%. This past expansion can be linked to progress in RNA biology research, an improved understanding of gene regulation mechanisms, the expansion of oncology research programs, the accessibility of advanced sequencing technologies, and a rise in translational medicine initiatives.
The epitranscriptomic therapies market size is projected to experience substantial growth in the coming years, reaching $4.2 billion by 2030 with a compound annual growth rate (CAGR) of 21.9%. This anticipated expansion during the forecast period is attributed to factors like increasing investments in RNA-based therapeutics, a rising demand for targeted cancer treatments, the broader adoption of personalized medicine approaches, heightened clinical trial activity in epitranscriptomics, and increased regulatory engagement for novel RNA therapies. Major trends expected in this period include the accelerated development of epitranscriptomic drug pipelines, the growing utilization of RNA modification profiling tools, an expansion of combination epitranscriptomic therapies, increasing integration of bioinformatics in therapy design, and an enhanced focus on precision medicine applications.
Download A Free Sample Report For Comprehensive Market Insights:
Epitranscriptomic Therapies Market Opportunity Drivers: What Is Creating New Revenue Potential?
The anticipated expansion of the epitranscriptomic therapies market is set to be driven by the escalating need for personalized medicine. This medical approach involves customizing healthcare decisions, treatments, and interventions to align with each patient’s unique characteristics, such as their genetic profile, lifestyle, and environment. The primary force behind the rising demand for personalized medicine is the increasing prevalence of chronic and complex diseases, as tailored treatments are more effective in addressing individual patient requirements and enhancing outcomes. Personalized medicine bolsters epitranscriptomic therapies by adapting treatments to an individual’s specific RNA modification patterns, thereby boosting therapeutic effectiveness while mitigating the risk of adverse effects. For instance, in February 2024, data from the Personalized Medicine Coalition, a US-based non-profit organization, revealed that the U.S. Food and Drug Administration (FDA) approved 16 new personalized treatments for rare disease patients in 2023, marking an increase from six in 2022. The personalized treatments newly approved in 2023 also encompassed seven cancer drugs and three for other diseases and conditions. Therefore, the growing demand for personalized medicine is a significant catalyst for the growth of the epitranscriptomic therapies market.
Epitranscriptomic Therapies Market Segmentation Trends And Revenue Drivers
The epitranscriptomic therapies market covered in this report is segmented –
1) By Therapy Type: Small Molecule Inhibitors; Ribonucleic Acid Modifying Enzymes; Antisense Oligonucleotides; Other Therapy Types
2) By Route of Administration: Injectable; Oral; Other Routes Of Administration
3) By Application: Cancer; Neurological Disorders; Metabolic Diseases; Infectious Diseases; Other Applications
4) By End-User: Hospitals; Research Institutes; Pharmaceutical And Biotechnology Companies; Other End-Users
Subsegments:
1) By Small Molecule Inhibitors: Methyltransferase Inhibitors; Demethylase Inhibitors; Reader Protein Inhibitors; Writer Enzyme Inhibitors; Eraser Enzyme Inhibitors
2) By Ribonucleic Acid Modifying Enzymes: Methyltransferase Enzymes; Demethylase Enzymes; Pseudouridine Synthase Enzymes; Adenosine Deaminase Enzymes; Cytidine Deaminase Enzymes
3) By Antisense Oligonucleotides: Gapmer Oligonucleotides; Splice Modulating Oligonucleotides; Translation Blocking Oligonucleotides; Exon Skipping Oligonucleotides; Gene Expression Silencing Oligonucleotides
4) By Other Therapy Types: Ribonucleic Acid Interference Based Therapies; Messenger Ribonucleic Acid Editing Therapies; Epitranscriptomic Vaccine Platforms; Gene Regulation Modulation Therapies; Combination Epitranscriptomic Therapies
Epitranscriptomic Therapies Market Innovation Trends Driving Future Development
Prominent companies within the epitranscriptomic therapies market are concentrating on forming strategic partnerships to create groundbreaking RNA-modifying cancer treatments. Strategic partnerships involve cooperative arrangements where organizations pool resources, knowledge, or capabilities to achieve common objectives, leading to quicker growth, reduced operational risks, and stronger market competitiveness. For example, in January 2026, STORM Therapeutics Ltd., a UK-based biotechnology company, collaborated with Alida Biosciences Inc., a US-based technology company, to further develop cancer therapies focused on epitranscriptomic mechanisms. This collaboration is centered on integrating AlidaBio’s EpiPlex and EpiScout platforms with STORM’s clinical trials for STC-15, a first-in-class METTL3 inhibitor. The partnership intends to identify and validate m6A RNA modification biomarkers that can predict patient responses and enhance therapeutic strategies. This joint effort combines drug development with advanced RNA profiling, representing a significant progression in epitranscriptomic cancer therapies.
#Epitranscriptomic Therapies Market Industry Leaders: Which Organizations Are Driving Competition?
Major companies operating in the epitranscriptomic therapies market are AstraZeneca PLC, GSK plc, Moderna Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Arcturus Therapeutics Holdings Inc., Arrakis Therapeutics Inc., AIRNA Corporation, CD Genomics, ProQR Therapeutics N.V., Nimbus Therapeutics LLC, Envisagenics Inc., Skyhawk Therapeutics Inc., Avidity Biosciences Inc., STORM Therapeutics Ltd., Omega Therapeutics Inc., Korro Bio Inc., Accent Therapeutics Inc., Alida Biosciences Inc., and O2nix Bio.
Access The Complete Epitranscriptomic Therapies Market Report:
Epitranscriptomic Therapies Market Leading Geography: Which Region Generates The Most Revenue?
North America was the largest region in the epitranscriptomic therapies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the epitranscriptomic therapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
